

Name of journal: *World Journal of Gastroenterology*

Manuscript NO.: 80756

Response to Reviewers and to Editor's comments

Dear Editor-in-Chief,

Thank you for providing us with the opportunity to review our manuscript, titled **"Chitin-glucan improves important pathophysiological features of irritable bowel syndrome"** (NO. 80756). We have addressed the comments from the Reviewer and Editorial Office point by point.

The manuscript has been improved according to these comments and the revised/added content has been highlighted with yellow color in the revised manuscript.

The new version of the manuscript has been reviewed by a **professional English language editing company (Editage)** and language has been further polished to reach Grade A Language Quality. The new certificate has been provided with the submission of the revised Manuscript.

Thanks for your attention,

Best Regards,

Christel Rousseaux

RESPONSES TO REVIEWERS

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors:

This is a report of preclinical laboratory animal experiments seeking to study the effects of chitin-glucan (CG) on irritable bowel induced in these animals. Although well conducted, preclinical animal experiments cannot quickly be extrapolated as effective human treatment. The following revisions are necessary:

1. Whether the treatment is really beneficial in humans, and whether CG can induce similar outcomes has clearly NOT been established. Therefore their conclusion in the Abstract that "CG decreased visceral perception and intestinal inflammation through master gene regulation and direct binding of microbial products, providing evidence-based CG treatment for patients with IBS or IBS-like symptoms" is clearly inappropriate and too strong. It must be changed.

Answer: Dear reviewer, thank you for your review and comments. We have made changes to the conclusion based on your comment. The sentence "CG decreased visceral perception and intestinal inflammation through master gene regulation and direct binding of microbial products, providing evidence-based CG treatment ..." has been replaced with "CG decreased visceral perception and intestinal inflammation through master gene regulation and direct binding of microbial products, suggesting that CG may constitute a new therapeutic strategy ..." (page 6/45)

2. Similarly present study suggests but certainly does not indicate that CG is valuable for IBS patients. therefore the core tip "This study indicated new capacities of chitin-glucan to target most pathophysiological mechanisms of IBS and its therapeutic potential as a promising new generation of prebiotics for patients with IBS or IBS-like symptoms" cannot be justified merely from preclinical animal studies without any human trials whatsoever.

Answer: Thank you for your comment. In response, the sentence "This study indicated...." has been replaced with "This study suggests ..." (page 2/44).

EDITORIAL OFFICE'S COMMENTS

Science editor:

3 Language evaluation: The English-language grammatical presentation needs to be improved to a certain extent. There are many errors in grammar and format, throughout the entire manuscript. Before final acceptance, the authors must provide the English Language Certificate issued by a professional English language editing company. Please visit the following website for the professional English language editing companies we recommend: <https://www.wjgnet.com/bpg/gerinfo/240>.

Answer: Dear Editor, thank for your comment. The new version of the manuscript has been reviewed by a **professional English language editing company** and language has been further polished to reach Grade A Language Quality. The new certificate for the English editing has been provided with the submission of the revised Manuscript.

4 Specific comments:

(1) Please provide the filled conflict-of-interest disclosure form.

Answer: The COI disclosure form has been provided with the submission of the new manuscript.

(2) Please provide the Figures cited in the original manuscript in the form of PPT. All text can be edited, including A, B, arrows, etc. All legends are incorrectly formatted and require a general title and explanation for each figure. Such as Figure 1 title. A: ; B: ; C: .

Answer: The editable figures have been provided in the form of a PPT with the submission of the new manuscript. Modifications have been made to the figures to ensure they meet the correct format.

(3) Please upload the approved grant application form(s) or funding agency copy of any approval document(s).

Answer: The document has been uploaded with the submission of the new manuscript.

(4) The “Article Highlights” section is missing. Please add the “Article Highlights” section at the end of the main text (and directly before the References).

Answer: A new section titled Highlights has been created in the revised manuscript.

Company editor-in-chief

When revising the manuscript, it is recommended that the author supplement and improve the highlights of the latest cutting-edge research results, thereby further improving the content of the manuscript. To this end, authors are advised to apply PubMed, or a new tool, the *Reference Citation Analysis (RCA)*, of which data source is PubMed. *RCA* is a unique artificial intelligence system for citation index evaluation of medical science and life science literature. In it, upon obtaining search results from the keywords entered by the author, "Impact Index Per Article" under "Ranked by" should be selected to find the latest highlight articles, which can then be used to further improve an article under preparation/peer-review/revision. Please visit our *RCA* database for more information at: <https://www.referencecitationanalysis.com/>, or visit PubMed at: <https://pubmed.ncbi.nlm.nih.gov/>.

Answer: Dear Editor-in-Chief, we utilized the "Reference citation analysis" tool to explore any new cutting-edge research results in the same scientific field that could potentially enhance the quality of the manuscript.

(1) Requirements for Figures: Please provide decomposable Figures (in which all components are movable and editable), organize them into a single PowerPoint file, and submit as “90756-Figures.pptx” on the system. The figures should be uploaded to the file destination of “Image File”. Please check and confirm whether the figures are original (i.e. generated de novo by the author(s) for this paper). If the picture is ‘original’, the author needs to add the following copyright information to the bottom right-hand side of the picture in PowerPoint (PPT): Copyright ©The Author(s). Please click to download the sample document: [Download](#).

Answer: Decomposable Figures have been compiled into a single PowerPoint File and will be submitted as “90756-Figures.pptx”, along with the revised manuscript.

Additionally, the phrase “Copyright ©The Author(s) 2022” has been included at the bottom right-hand side of all figures in the PowerPoint file.

(2) Requirements for Tables: Please provide decomposable Tables (in which all components are movable and editable), organize them into a single Word file, and submit as “**90756-Tables.docx**” on the system. The tables should be uploaded to the file destination of “Table File”.

Answer: Decomposable Tables have been provided into a single PowerPoint File and will be submitted as “**90756-Tables.pptx**” along with the revised manuscript.